University Of Heidelberg Medical Center
Clinical trials sponsored by University Of Heidelberg Medical Center, explained in plain language.
-
New combo therapy aims to deepen remission in multiple myeloma
Disease control Recruiting nowThis phase 3 trial tests whether adding isatuximab to iberdomide maintenance therapy after a stem cell transplant can reduce cancer cells in the bone marrow more than iberdomide alone. About 411 adults with newly diagnosed multiple myeloma will participate. The goal is to see if …
Phase: PHASE3 • Sponsor: University of Heidelberg Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New cocktail of drugs aims to tackle multiple myeloma early
Disease control Recruiting nowThis phase 2 trial is testing several new drug combinations, including teclistamab, talquetamab, and JNJ-79635322, in 160 people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see if these combinations are safe and more effective…
Phase: PHASE2 • Sponsor: University of Heidelberg Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC